Anbio Biotechnology Class A Ordinary Shares (NNNN) — 分析摘要
Anbio Biotechnology Class A Ordinary Shares(NNNN)的市值为437.60百万美元,最近一年的营收同比增长了+5.6%。净利润率为74.1%。当前市盈率为68.3倍。
核心要点
- 营收同比变化+5.6%
- 净利润率74.1%
- 市盈率68.3倍
NNNN的营收增长为+5.6%,市盈率为68.3倍。
Anbio Biotechnology Class A Ordinary Shares (NNNN)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
经营现金流为负,但净利润仍为正。
营业利润率为 66.7% — 异常高,通常仅见于垄断或IP密集型企业
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
员工人数
27
Exchange
XNAS
需要至少 3 年年度财务数据来评估竞争壁垒。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。